Cited by 830Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchLung Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations

Sequist, Lecia V., Martins, Renato G., Spigel, David, Grunberg, Steven M., Spira, Alexander, Jänne, Pasi A., Joshi, Victoria A., McCollum, David, Evans, Tracey L., Muzikansky, Alona, Kuhlmann, Georgiana L., Han, Moon, Goldberg, Jonathan S., Settleman, Jeffrey, Iafrate, A. John, Engelman, Jeffrey A., Haber, Daniel A., Johnson, Bruce E., Lynch, Thomas J.·2008·Journal of Clinical Oncology

DOI 10.1200/jco.2007.14.8494

Open this paper in CoChat — free account

Abstract

PURPOSE: Somatic mutations in the epidermal growth factor receptor (EGFR) correlate with increased response in patients with non-small-cell lung cancer (NSCLC) treated with EGFR tyrosine kinase inhibitors (TKIs). The multicenter iTARGET trial prospectively examined first-line gefitinib in advanced NSCLC patients harboring EGFR mutations and explored the significance of EGFR mutation subtypes and TKI resistance mechanisms. PATIENTS AND METHODS: Chemotherapy-naïve patients with advanced NSCLC with >or= 1 clinical characteristic associated with EGFR mutations underwent direct DNA sequencing of tumor tissue EGFR exons 18 to 21. Patients found to harbor any EGFR mutation were treated with gefitinib 250 mg/d until progression or unacceptable toxicity. The primary outcome was response rate. RESULTS: Ninety-eight patients underwent EGFR screening and mutations were detected in 34 (35%). EGFR mutations were primarily exon 19 deletions (53%) and L858R (26%) though 21% of mutation-positive cases had less common subtypes including exon 20 insertions, T790M/L858R, G719A, and L861Q. Thirty-one patients received gefitinib. The response rate was 55% (95% CI, 33 to 70) and median progression-free survival was 9.2 months (95% CI, 6.2 to 11.8). Therapy was well tolerated; 13% of patients had grade 3 toxicities including one grade 3 pneumonitis. Two patients with classic activating mutations exhibited de novo gefitinib resistance and had concurrent genetic anomalies usually associated with acquired TKI resistance, specifically the T790M EGFR mutation and MET amplification. CONCLUSION: First-line therapy with gefitinib administered in a genotype-directed fashion to patients with advanced NSCLC harboring EGFR mutations results in very favorable clinical outcomes with good tolerance. This strategy should be compared with combination chemotherapy, the current standard of care.

Integrity signals

Registry

Crossref · 10.1200/jco.2007.14.8494

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Self-citation
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citation
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Self-citation
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Self-citation
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Self-citation

Flagged first, then by citations

Show all 46 references

Sorted by citations

Items 101–200 of 830

Customized Treatment in Non-Small-Cell Lung Cancer Based on EGFR Mutations and BRCA1 mRNA Expression
Rosell, R., Perez‐Roca, L., Sánchez, J. J., Cobo, M., Morán, T., CHAIB-OUKADOUR, I., Provencio, M., Dómine, M., Sala, M. Á., Jiménez, U., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005133 · Cited by 164
Acquired Resistance of Non–Small Cell Lung Cancer Cells to MET Kinase Inhibition Is Mediated by a Switch to Epidermal Growth Factor Receptor Dependency
McDermott, U., Pusapati, R. V., Christensen, J. G., Gray, N. S., & Settleman, J. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3620 · Cited by 161
Self-citation
T790M and acquired resistance of EGFR TKI: a literature review of clinical reports.
Ma, C., Wei, S., & Song, Y. J. (2011) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2010.12.02 · Cited by 158
EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB
Lin, K., Cheng, J., Yang, T., Li, Y., & Zhu, B. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.05.030 · Cited by 152
The Microenvironment of Lung Cancer and Therapeutic Implications
Mittal, V., Rayes, T. E., Narula, N., McGraw, T. E., Altorki, N. K., & Barcellos‐Hoff, M. H. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-24932-2_5 · Cited by 154
Reversal of Warburg Effect and Reactivation of Oxidative Phosphorylation by Differential Inhibition of EGFR Signaling Pathways in Non–Small Cell Lung Cancer
Rosa, V. D., Iommelli, F., Monti, M., Fonti, R., Votta, G., Stoppelli, M. P., & Vecchio, S. D. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0375 · Cited by 152
Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer
Hammerman, P. S., Janne, P. A., & Johnson, B. E. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0189 · Cited by 147
Self-citation
Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations
Wang, J., Wang, B., Chu, H., & Yao, Y. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s106399 · Cited by 143
Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures
Lee, K. H. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.001 · Cited by 142
Clinical outcomes in non‐small‐cell lung cancer patients with EGFR mutations: pooled analysis
Paz-Ares, L. G., Soulières, D., Melezínek, I., Moecks, J., Keil, L., Mok, T. S. K., Rosell, R., & Klughammer, B. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00991.x · Cited by 141
Tumor heterogeneity in the clinic: is it a real problem?
Jankú, F. (2013) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834013517414 · Cited by 144
Molecularly Targeted Therapies in Non–Small-Cell Lung Cancer Annual Update 2014
Morgensztern, D., Campo, M. J., Dahlberg, S. E., Doebele, R. C., Garon, E. B., Gerber, D. E., Goldberg, S. B., Hammerman, P. S., Heist, R. S., Hensing, T. A., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000405 · Cited by 138
Self-citation
Mutations and Response to Epidermal Growth Factor Receptor Inhibitors
Laurent‐Puig, P., Lièvre, A., & Blons, H. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0905 · Cited by 134
Novel Therapeutic Targets in Non-small Cell Lung Cancer
Jankú, F., Garrido‐Laguna, I., Petruzelka, L. B., Stewart, D. J., & Kurzrock, R. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31822944b3 · Cited by 133
Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas that Harbor EGFR Mutations
Janjigian, Y. Y., Park, B. J., Zakowski, M. F., Ladanyi, M., Pao, W. J., D’Angelo, S. P., Kris, M. G., Shen, R., Zheng, J., & Azzoli, C. G. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318202bffe · Cited by 131
EGFR-mutated oncogene-addicted non-small cell lung cancer: Current trends and future prospects
Soria, J., Mok, T. S. K., Cappuzzo, F., & Janne, P. A. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.10.003 · Cited by 131
Self-citation
Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence
Gridelli, C., de Marinis, F., Maïo, M. D., Cortinovis, D. L., Cappuzzo, F., & Mok, T. S. K. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2010.12.008 · Cited by 133
Quantification and Dynamic Monitoring of EGFR T790M in Plasma Cell-Free DNA by Digital PCR for Prognosis of EGFR-TKI Treatment in Advanced NSCLC
Wang, Z., Chen, R., Wang, S., Zhong, J., Wu, M., Zhao, J., Duan, J., Zhuo, M., An, T., Wang, Y., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110780 · Cited by 130
Personalized Cancer Therapy With Selective Kinase Inhibitors: An Emerging Paradigm in Medical Oncology
McDermott, U., & Settleman, J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.9054 · Cited by 131
Self-citation
Spatial Heterogeneity in Drug Concentrations Can Facilitate the Emergence of Resistance to Cancer Therapy
Fu, F., Nowak, M. A., & Bonhoeffer, S. (2015) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004142 · Cited by 129
MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations
Tanizaki, J., Okamoto, I., Okamoto, K., Takezawa, K., Kuwata, K., Yamaguchi, H., & Nakagawa, K. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31822591e9 · Cited by 127
EGFR-Targeted Therapy for Non-Small Cell Lung Cancer: Focus on EGFR Oncogenic Mutation
Antonicelli, A., Cafarotti, S., Indini, A., Galli, A., Russo, A., Cesario, A., Lococo, F., Russo, P., Mainini, A. F., Bonifati, L. G., et al. (2013) · International Journal of Medical Sciences · doi:10.7150/ijms.4609 · Cited by 131
Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors
Juchum, M., Günther, M., & Laufer, S. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.05.002 · Cited by 126
Oncogenic Pathways, Molecularly Targeted Therapies, and Highlighted Clinical Trials in Non–Small-Cell Lung Cancer (NSCLC)
Reungwetwattana, T., Weroha, S. J., & Molina, J. R. (2011) · Clinical Lung Cancer · doi:10.1016/j.cllc.2011.09.004 · Cited by 127
Tumor BRCA1, RRM1 and RRM2 mRNA Expression Levels and Clinical Response to First-Line Gemcitabine plus Docetaxel in Non-Small-Cell Lung Cancer Patients
Boukovinas, I., Papadaki, C., Méndez, P., Tarón, M., Mavroudis, D., Koutsopoulos, A. V., Sanchez-Ronco, M., Sánchez, J. J., Trypaki, M., Staphopoulos, E., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003695 · Cited by 125
Effect of microRNA-135a on Cell Proliferation, Migration, Invasion, Apoptosis and Tumor Angiogenesis Through the IGF-1/PI3K/Akt Signaling Pathway in Non-Small Cell Lung Cancer
Zhou, Y., Li, S., Li, J., Wang, D., & Li, Q. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479207 · Cited by 125
State of the Art: Response Assessment in Lung Cancer in the Era of Genomic Medicine
Nishino, M., Hatabu, H., Johnson, B. E., & McLoud, T. C. (2014) · Radiology · doi:10.1148/radiol.14122524 · Cited by 124
Self-citation
Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification
Tanizaki, J., Okamoto, I., Sakai, K., & Nakagawa, K. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.322 · Cited by 122
Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: Focus on epidermal growth factor receptor mutation testing and mutation-positive patients
Roengvoraphoj, M., Tsongalis, G. J., Dragnev, K. H., & Rigas, J. R. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.05.001 · Cited by 121
Pattern of Failure Analysis in Metastatic EGFR-Mutant Lung Cancer Treated with Tyrosine Kinase Inhibitors to Identify Candidates for Consolidation Stereotactic Body Radiation Therapy
Al-Halabi, H., Sayegh, K., Digamurthy, S. R., Niemierko, A., Piotrowska, Z., Willers, H., & Sequist, L. V. D. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000648 · Cited by 121
Self-citation
Docosahexaenoic acid alters epidermal growth factor receptor-related signaling by disrupting its lipid raft association
Rogers, K. R., Kikawa, K. D., Mouradian, M. H., Hernandez, K., McKinnon, K. M., Ahwah, S. M., & Pardini, R. S. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq111 · Cited by 118
Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization
Cho, J., Chen, L., Sangji, N., Okabe, T., Yonesaka, K., Francis, J. M., Flavin, R. J., Johnson, W., Kwon, J., Yu, S., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1145 · Cited by 117
Self-citation
Molecular Pathology of Non–Small Cell Lung Cancer
Aisner, D. L., & Marshall, C. B. (2012) · American Journal of Clinical Pathology · doi:10.1309/ajcpfr12wjkceezz · Cited by 119
Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations
König, D., Prince, S. S., & Rothschild, S. I. (2021) · Cancers · doi:10.3390/cancers13040804 · Cited by 119
EGFRMutation Is a Better Predictor of Response to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Carcinoma Than FISH, CISH, and Immunohistochemistry
Sholl, L. M., Xiao, Y., Joshi, V. A., Yeap, B. Y., Cioffredi, L., Jackman, D. M., Lee, C., Janne, P. A., & Lindeman, N. I. (2010) · American Journal of Clinical Pathology · doi:10.1309/ajcpst1cthzs3psz · Cited by 116
Self-citation
Detection of epidermal growth factor receptor mutations in plasma by mutant‐enriched PCR assay for prediction of the response to gefitinib in patients with non‐small‐cell lung cancer
He, C., Liu, M., Zhou, C., Zhang, J., Ouyang, M., Zhong, N., & Xu, J. (2009) · International Journal of Cancer · doi:10.1002/ijc.24653 · Cited by 111
A Pilot Study of Volume Measurement as a Method of Tumor Response Evaluation to Aid Biomarker Development
Zhao, B., Oxnard, G. R., Moskowitz, C. S., Kris, M. G., Pao, W. J., Guo, P., Rusch, V. W., Ladanyi, M., Rizvi, N. A., & Schwartz, L. H. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0125 · Cited by 111
Uncommon Epidermal Growth Factor Receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance
Massarelli, E., Johnson, F. M., Erickson, H. S., Wistuba, I. I., & Papadimitrakopoulou, V. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.01.018 · Cited by 110
Targeting EGFR in Lung Cancer: Current Standards and Developments
Díaz-Serrano, A., Gella, P., Jiménez, E., Zugazagoitia, J., & Paz-Ares Rodríguez, L. (2018) · Drugs · doi:10.1007/s40265-018-0916-4 · Cited by 108
Targeting MET Amplification as a New Oncogenic Driver
Kawakami, H., Okamoto, I., Okamoto, W., Tanizaki, J., Nakagawa, K., & Nishio, K. (2014) · Cancers · doi:10.3390/cancers6031540 · Cited by 107
Rare cancers: a sea of opportunity
Boyd, N., Dancey, J. E., Gilks, C. B., & Huntsman, D. D. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00386-1 · Cited by 107
CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance
Nilsson, M. B., Yang, Y., Heeke, S., Patel, S. A., Poteete, A., Udagawa, H., Elamin, Y. Y., Moran, C. A., Kashima, Y., Arumugam, T., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.01.007 · Cited by 112
Mechanisms of tumor resistance to EGFR-targeted therapies
Hopper-Borge, E. A., Nasto, R. E., Ratushny, V., Weiner, L. M., Golemis, E. A., & Astsaturov, I. A. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14712590902735795 · Cited by 109
Curcumin: Updated Molecular Mechanisms and Intervention Targets in Human Lung Cancer
Ye, M.-X., Li, Y., Yin, H., & Zhang, J. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13033959 · Cited by 108
Effective Treatment of Lung Adenocarcinoma Harboring EGFR-Activating Mutation, T790M, and cis-C797S Triple Mutations by Brigatinib and Cetuximab Combination Therapy
Wang, Y., Yang, N., Zhang, Y., Li, L., Han, R., Zhu, M., Feng, M., Chen, H., Lizaso, A., Tian, Q., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.04.014 · Cited by 104
Genotype-driven therapies for non-small cell lung cancer: focus on EGFR , KRAS and ALK gene abnormalities
Gaughan, E. M., & Costa, D. B. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834010397569 · Cited by 104
Screening for EGFR and KRAS Mutations in Endobronchial Ultrasound Derived Transbronchial Needle Aspirates in Non-Small Cell Lung Cancer Using COLD-PCR
Santis, G., Angell, R., Nickless, G., Quinn, A., Herbert, A., Cane, P., Spicer, J. F., Breen, R. A. M., McLean, E., & Tobal, K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025191 · Cited by 99
MicroRNA as tools and therapeutics in lung cancer
Barger, J. F., & Nana-Sinkam, S. P. (2015) · Respiratory Medicine · doi:10.1016/j.rmed.2015.02.006 · Cited by 100
Unraveling the Genetics of Cancer: Genome Sequencing and Beyond
Wong, K. M., Hudson, T. J., & McPherson, J. D. (2011) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-082509-141532 · Cited by 96
Only a Subset of Met-Activated Pathways Are Required to Sustain Oncogene Addiction
Bertotti, A., Burbridge, M. F., Gastaldi, S., Galimi, F., Torti, D., Médico, E., Giordano, S., Corso, S., Rolland-Valognes, G., Lockhart, B. P., et al. (2009) · Science Signaling · doi:10.1126/scisignal.2000643 · Cited by 103
Circulating tumor cells versus circulating tumor DNA in lung cancer—which one will win?
Fariñas, S. C., Lewintre, E. J., Herreros‐Pomares, A., & Camps, C. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.10.02 · Cited by 97
A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R
Ke, E., Zhou, Q. H., Zhang, Q.-Y., Su, J., Chen, Z., Zhang, X., Xu, C., Yang, J., Tu, H., Yan, H., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.05.018 · Cited by 95
Liquid Biopsy in Lung Cancer: Clinical Applications of Circulating Biomarkers (CTCs and ctDNA)
Lim, M., Kim, C., Sunkara, V., Kim, M., & Cho, Y. (2018) · Micromachines · doi:10.3390/mi9030100 · Cited by 97
Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva
Horowitz, N. S., Olawaiye, A. B., Borger, D. R., Growdon, W. B., Krasner, C. N., Matulonis, U. A., Liu, J. F., Lee, J. D., Brard, L., & Dizon, D. S. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.06.028 · Cited by 96
Ligand-Dependent Platelet-Derived Growth Factor Receptor (PDGFR)-α Activation Sensitizes Rare Lung Cancer and Sarcoma Cells to PDGFR Kinase Inhibitors
McDermott, U., Ames, R. Y., Iafrate, A. J., Maheswaran, S., Stubbs, H., Greninger, P., McCutcheon, K., Milano, R. J., Tam, A., Lee, D. W., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4327 · Cited by 96
Self-citation
Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM
Song, K.-A., Niederst, M. J., Lochmann, T. L., Hata, A. N., Kitai, H., Ham, J., Floros, K. V., Hicks, M. A., Hu, H., Mulvey, H. E., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1577 · Cited by 95
Self-citation
Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma
Deshpande, V., Nduaguba, A. M., Zimmerman, S. M., Kehoe, S. M., MacConaill, L. E., Lauwers, G. Y., Ferrone, C. R., Bardeesy, N. M., Zhu, A. X., & Hezel, A. F. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-60 · Cited by 95
Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: Perplexity and solution
Li, K., Yang, M., Liang, N., & Li, S. (2017) · Oncology Reports · doi:10.3892/or.2017.5409 · Cited by 95
Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients
Suh, C. H., Park, H. S., Kim, K. W., Pyo, J., Hatabu, H., & Nishino, M. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.06.032 · Cited by 97
Gefitinib versus pemetrexed as second‐line treatment in patients with nonsmall cell lung cancer previously treated with platinum‐based chemotherapy (KCSG‐LU08‐01)
Sun, J., Lee, K. H., Kim, S.-W., Lee, K. H., Min, Y. J., Yun, H., Kim, H. K., SONG, H. S., Kim, Y. H., Kim, B., et al. (2012) · Cancer · doi:10.1002/cncr.27630 · Cited by 96
Performance evaluation of indel calling tools using real short-read data
Hasan, M. S., Wu, X., & Zhang, L. (2015) · Human Genomics · doi:10.1186/s40246-015-0042-2 · Cited by 95
Lessons Learned from Two Decades of Anticancer Drugs
Liu, Z., Delavan, B., Roberts, R. A., & Tong, W. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.06.005 · Cited by 95
Common EGFR -Mutated Subgroups (Del19/L858R) in Advanced Non-Small-Cell Lung Cancer: Chasing Better Outcomes with Tyrosine Kinase Inhibitors
Reguart, N., & Remon, J. (2015) · Future Oncology · doi:10.2217/fon.15.15 · Cited by 91
Afatinib, Erlotinib and Gefitinib in the First-Line Therapy of EGFR Mutation-Positive Lung Adenocarcinoma: A Review
Köhler, J., & Schüler, M. (2013) · Oncology Research and Treatment · doi:10.1159/000354627 · Cited by 93
Systems pharmacology and genome medicine: a future perspective
Wist, A. D., Berger, S., & Iyengar, R. (2009) · Genome Medicine · doi:10.1186/gm11 · Cited by 90
Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer
Traynor, A. M., Schiller, J. H., Stabile, L. P., Kolesar, J., Eickhoff, J. C., Đačić, S., HOANG, T. N., Dubey, S., Marcotte, S. M., & Siegfried, J. M. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2008.07.002 · Cited by 90
Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy
Gazdar, A. F. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9201-z · Cited by 99
Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies
Leto, S. M., & Trusolino, L. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1161-2 · Cited by 87
AC0010, an Irreversible EGFR Inhibitor Selectively Targeting Mutated EGFR and Overcoming T790M-Induced Resistance in Animal Models and Lung Cancer Patients
Xu, X., Mao, L., Xu, W., Tang, W., Zhang, X., Xi, B., Xu, R., Fang, X., Liu, J., Fang, C., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0281 · Cited by 87
Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis
Sheng, M., Wang, F., Zhao, Y., Li, S., Wang, X., Shou, T., Luo, Y., & Tang, W. (2015) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-015-1966-0 · Cited by 85
CT Slice Thickness and Convolution Kernel Affect Performance of a Radiomic Model for Predicting EGFR Status in Non-Small Cell Lung Cancer: A Preliminary Study
Li, Y., Lü, L., Xiao, M., Dercle, L., Huang, Y., Zhang, Z., Schwartz, L. H., Li, D., & Zhao, B. (2018) · Scientific Reports · doi:10.1038/s41598-018-36421-0 · Cited by 87
Cost Effectiveness of Personalized Therapy for First-Line Treatment of Stage IV and Recurrent Incurable Adenocarcinoma of the Lung
Handorf, E. A., McElligott, S. C., Vachani, A., Langer, C. J., Bristol, M. N., Armstrong, K., & Asch, D. A. (2012) · Journal of Oncology Practice · doi:10.1200/jop.2011.000502 · Cited by 85
Erlotinib at a Dose of 25 mg Daily for Non-small Cell Lung Cancers with EGFR Mutations
Yeo, W.-L., Riely, G. J., Yeap, B. Y., Lau, M. W., Warner, J. L., Bodio, K., Huberman, M. S., Kris, M. G., Tenen, D. G., Pao, W. J., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181dd1386 · Cited by 82
Frequency and Type of Epidermal Growth Factor Receptor Mutations in African Americans with Non-small Cell Lung Cancer
Coté, M. L., Haddad, R., Edwards, D. J., Atikukke, G., Gadgeel, S. M., Soubani, A. O., Lonardo, F., Bepler, G., Schwartz, A. G., & Ethier, S. P. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31820a0ec0 · Cited by 81
The progress of multimodal imaging combination and subregion based radiomics research of cancers
Zhang, L., Wang, Y., Peng, Z., Weng, Y., Fang, Z., Xiao, F., Zhang, C., Fan, Z., Huang, K., Zhu, Y., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.71046 · Cited by 82
Targeted Therapies for Non–Small Cell Lung Cancer: An Evolving Landscape
Pal, S. K., Figlin, R. A., & Reckamp, K. L. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0239 · Cited by 81
Epidermal growth factor receptor in relation to tumor development: EGFR‐targeted anticancer therapy
Okamoto, I. (2009) · FEBS Journal · doi:10.1111/j.1742-4658.2009.07449.x · Cited by 81
Molecular Predictors of EGFR-TKI Sensitivity in Advanced Non–small Cell Lung Cancer
Zhang, X., & Chang, A. Y. (2008) · International Journal of Medical Sciences · doi:10.7150/ijms.5.209 · Cited by 79
Resistance to EGF-R (erbB-1) and VEGF-R modulating agents
Dempke, W. C. M., & Heinemann, V. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.11.038 · Cited by 78
Treatment of metastatic cervical cancer: Future directions involving targeted agents
Díaz-Padilla, I., Monk, B. J., MacKay, H. J., & Oaknin, A. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.07.006 · Cited by 80
Seize the opportunity
Clark, D. P. (2009) · Cancer Cytopathology · doi:10.1002/cncy.20045 · Cited by 80
High T790M detection rate in TKI-naive NSCLC with EGFR sensitive mutation: truth or artifact?
Ye, X., Zhu, Z.-Z., Zhong, L., Lu, Y., Sun, Y., Yin, X., Yang, Z., Zhu, G., & Ji, Q. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31829f691f · Cited by 79
Early Accelerated Approval for Highly Targeted Cancer Drugs
Chabner, B. A. (2011) · New England Journal of Medicine · doi:10.1056/nejmp1100548 · Cited by 79
Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives
Chen, H., & Cheng, X. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s66502 · Cited by 81
Targeted therapies in the treatment of advanced/metastatic NSCLC
Pallis, A. G., Serfass, L., Dziadziuszko, R., van Meerbeeck, J. P., Fennell, D. A., Lacombe, D., Welch, J., & Gridelli, C. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.06.005 · Cited by 78
EGFR-Targeted Therapies in Lung Cancer: Predictors of Response and Toxicity
Heist, R. S., & Christiani, D. C. (2008) · Pharmacogenomics · doi:10.2217/14622416.10.1.59 · Cited by 81
Acquisition of cancer stem cell‐like properties in non‐small cell lung cancer with acquired resistance to afatinib
Hashida, S., Yamamoto, H., Shien, K., Miyoshi, Y., Ohtsuka, T., Suzawa, K., Watanabe, M., Maki, Y., Soh, J., Asano, H., et al. (2015) · Cancer Science · doi:10.1111/cas.12749 · Cited by 79
Challenges in the Use of Targeted Therapies in Non–Small Cell Lung Cancer
Rivera‐Concepción, J., Uprety, D., & Adjei, A. A. (2022) · Cancer Research and Treatment · doi:10.4143/crt.2022.078 · Cited by 84
EGFR T790M resistance mutation in non small-cell lung carcinoma
Denis, M. G., Vallée, A., & Théoleyre, S. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.01.039 · Cited by 76
CNS metastases in non-small-cell lung cancer: Current role of EGFR-TKI therapy and future perspectives
Berger, L. A., Riesenberg, H., Bokemeyer, C., & Atanackovic, D. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.02.004 · Cited by 73
cIAP2 Upregulated by E6 Oncoprotein via Epidermal Growth Factor Receptor/Phosphatidylinositol 3-Kinase/AKT Pathway Confers Resistance to Cisplatin in Human Papillomavirus 16/18–Infected Lung Cancer
Wu, H.-H., Wu, J., Cheng, Y., Chen, C.-Y., Lee, M.-C., Goan, Y.-G., & Lee, H. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0020 · Cited by 74
Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations
Won, Y., Han, J., Lee, G. K., Park, S.-Y., Lim, K. Y., Yoon, K., Yun, T., Kim, H. T., & Lee, J. S. (2011) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2011-200169 · Cited by 75
Association of Polymorphisms inAKT1andEGFRwith Clinical Outcome and Toxicity in Non–Small Cell Lung Cancer Patients Treated with Gefitinib
Giovannetti, E., Zucali, P. A., Peters, G. J., Cortesi, F., D’Incecco, A., Smit, E. F., Falcone, A., Burgers, J. A., Santoro, A., Danesi, R., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0665 · Cited by 74
Overview of Gefitinib in Non-small Cell Lung Cancer: An Asian Perspective
Jiang, H. (2008) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyn139 · Cited by 74
Oligosaccharyltransferase Inhibition Overcomes Therapeutic Resistance to EGFR Tyrosine Kinase Inhibitors
Sambrooks, C. L., Baro, M., Quijano, A., Narayan, A., Cui, W., Greninger, P., Egan, R. K., Patel, A. A., Benes, C. H., Saltzman, W. M., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0505 · Cited by 74
Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors
Nishino, M., Cardarella, S., Dahlberg, S. E., Jackman, D. M., Ramaiya, N. H., Hatabu, H., Rabin, M. S., Janne, P. A., & Johnson, B. E. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.11.007 · Cited by 74
Self-citation
Miniaturized nuclear magnetic resonance platform for detection and profiling of circulating tumor cells
Castro, C. M., Ghazani, A. A., Chung, J., Shao, H., Issadore, D., Yoon, T., Weissleder, R., & Lee, H. (2013) · Lab on a Chip · doi:10.1039/c3lc50621e · Cited by 73
Next generation oncology drug development: opportunities and challenges
Gutierrez, M. E., Kummar, S., & Giaccone, G. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.38 · Cited by 71
the 11q13‐q14 amplicon: Clinicopathological correlations and potential drivers
Wilkerson, P. M., & Reis-Filho, J. S. (2012) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22037 · Cited by 70
Circulating Cell-Free DNA in Plasma of Never Smokers with Advanced Lung Adenocarcinoma Receiving Gefitinib or Standard Chemotherapy as First-Line Therapy
Lee, Y. J., Yoon, K., Han, J., Kim, H. T., Yun, T., Lee, G. K., Kim, H. Y., & Lee, J. S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0400 · Cited by 70

Authors: Sequist, L. V., Martins, R. G., Spigel, D., Grunberg, S. M., Spira, A., Jänne, P. A., Joshi, V. A., McCollum, D., Evans, T. L., Muzikansky, A., Kuhlmann, G. L., Han, M., Goldberg, J. S., Settleman, J., Iafrate, A. J., Engelman, J. A., Haber, D. A., Johnson, B. E., & Lynch, T. J.
Affiliations: Brigham and Women's Hospital (US)
From the Massachusetts General Hospital Cancer Center; Dana-Farber Cancer Institute and Department of Medicine, Brigham and Women's Hospital; Department of Pathology, Massachusetts General Hospital; Department of Biostatistics, Massachusetts General Hospital, Boston; Harvard Medical School/Partners Health Care Center for Genetics and Genomics, Cambridge, MA; University of Washington, Seattle, WA; Sarah Cannon Research Institute, Nashville, TN; Fletcher Allen Health Care, Burlington, VT; Fairfax-Northern...
ORCID: Sequist, Lecia V.
Martins, Renato G.
Spigel, David
Spira, Alexander
Evans, Tracey L.
Muzikansky, Alona
Han, Moon
Settleman, Jeffrey
Iafrate, A. John
Engelman, Jeffrey A.
Haber, Daniel A.
Johnson, Bruce E.
Lynch, Thomas J.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2008-05-20
Volume: 26
Issue: 15
Pages: 2442-2449
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2007.14.8494
OpenAlex: W2101329867
Cited by: 820
References: 46
Citations by year: 2026: 4 · 2025: 14 · 2024: 9 · 2023: 11 · 2022: 20 · 2021: 22 · 2020: 34 · 2019: 29 · 2018: 51 · 2017: 51 · 2016: 54 · 2015: 57 · 2014: 68 · 2013: 69 · 2012: 60
FWCI: 81.10
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords: gefitinib, non-small cell lung cancer, EGFR mutation, first-line therapy, EGFR tyrosine kinase inhibitors, exon 19 deletion, L858R mutation, T790M mutation, MET amplification, progression-free survival, response rate, pneumonitis, genotype-directed therapy
MeSH terms: Gefitinib, Adenocarcinoma, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Neoplasm Staging, Prospective Studies, Quinazolines, Survival Rate, Central Nervous System Neoplasms, Treatment Outcome, In Situ Hybridization, Fluorescence, Carcinoma, Large Cell, Disease-Free Survival, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks